33-OR: ADA Presidents' Select Abstract: Glycemic Outcomes over 12 Months in Very Young Children with the Omnipod 5 Automated Insulin Delivery (AID) System
DESALVO D, BODE B, FORLENZA G, LAFFEL L, BUCKINGHAM B, CRIEGO A, SCHOELWER M, MACLEISH S, SHERR J, HANSEN D, LY T. 33-OR: ADA Presidents' Select Abstract: Glycemic Outcomes over 12 Months in Very Young Children with the Omnipod 5 Automated Insulin Delivery (AID) System. Diabetes 2022, 71 DOI: 10.2337/db22-33-or.Peer-Reviewed Original ResearchDiabetic ketoacidosisSevere hypoglycemiaMannKind CorporationGlycemic outcomesExtension studyEpisodes of diabetic ketoacidosisOccurrence of severe hypoglycemiaNational Institute of DiabetesDigestive and Kidney DiseasesCenter for Health ResearchChildren aged 2Type 1 diabetesStandard therapySafety endpointsPivotal studiesPotential long-term benefitsKidney diseaseStudy groupGlucose targetsLong-term benefitsSpeakers bureauImprove glycemic outcomesAged 2MedtronicGlycemic benefits765-P: Glycemic Outcomes across Total Daily Insulin Doses with the Omnipod 5 Automated Insulin Delivery System (AID) among People with Type 1 Diabetes (T1D) Ages 2 to 70 Years
SCHOELWER M, BODE B, CARLSON A, CRIEGO A, FORLENZA G, WEINSTOCK R, HANSEN D, BUCKINGHAM B, MEHTA S, LAFFEL L, SHERR J, LEVY C, HIRSCH I, MACLEISH S, DESALVO D, SHAH V, BHARGAVA A, JONES T, ALEPPO G, GURLIN R, LY T. 765-P: Glycemic Outcomes across Total Daily Insulin Doses with the Omnipod 5 Automated Insulin Delivery System (AID) among People with Type 1 Diabetes (T1D) Ages 2 to 70 Years. Diabetes 2022, 71 DOI: 10.2337/db22-765-p.Peer-Reviewed Original ResearchDaily insulin doseMannKind CorporationInsulin doseGlycemic outcomesEvaluate glycemic outcomesHigher TIRNational Institute of DiabetesDigestive and Kidney DiseasesCenter for Health ResearchType 1 diabetesEli Lilly and CompanySpeakers bureauInsulin requirementsAid useKidney diseaseInsulin needsMannKindCohort of peopleMedtronicTherapy phaseAged 2Janssen PharmaceuticalsOlder ageDiabetesT1D92-OR: Persistence of Impaired Awareness of Hypoglycemia, Severe Hypoglycemic Events, and Suboptimal Glycemic Control Despite Advanced Diabetes Technologies
PETTUS J, LIU J, TITIEVSKY L, HAGAN K, LIU T, CHANDARANA K, GAGLIA J, WOLF W, BISPHAM J, CHAPMAN K, FINAN D, SHERR J. 92-OR: Persistence of Impaired Awareness of Hypoglycemia, Severe Hypoglycemic Events, and Suboptimal Glycemic Control Despite Advanced Diabetes Technologies. Diabetes 2022, 71 DOI: 10.2337/db22-92-or.Peer-Reviewed Original ResearchImpaired awareness of hypoglycemiaSevere hypoglycemic eventsRate of severe hypoglycemic eventsAwareness of hypoglycemiaGlycemic controlContinuous glucose monitoringHypoglycemic eventsPrevalence of impaired awareness of hypoglycemiaHybrid closed-loop systemProportion of patientsTarget glycemic controlNational Institute of DiabetesSuboptimal glycemic controlDigestive and Kidney DiseasesT1D Exchange RegistryPatient cohortMedical historyKidney diseaseNon-CGM usersSelf-reported medical historyT1D treatment